Emily Kay Husain Casabar, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Emily Kay Husain Casabar’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A22896 · Current
Licensed to practise in California · since 1968 · expires 2027-03-31 · University of California San Francisco School of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$32,095
Medicare paid this office $32,095 for 193 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 105 | $14,211 | $99 |
| Return visit (30+ min) | 115 | $13,414 | $85 |
| New patient visit (60+ min) | 28 | $3,197 | $114 |
Who their Medicare patients are
193 Original Medicare patients in 2024. Average age 76 · Under 65 8% · 85 and older 15% · Women 66% · Also on Medicaid 23% · Health risk score 2.01. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 72% · COPD 60% · Coronary heart disease 36% · Chronic kidney disease 32% · Diabetes 24% · Heart failure 24% · Depression 23% · Cancer 22% · Atrial fibrillation 20% · Stroke 7%.
The office billed $135,454, Medicare allowed $45,143 and paid $32,095; for 354 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 193 | 354 | 76 | 2.01 | $135,454 | $32,095 |
| 2023 | 219 | 435 | 75 | 1.68 | $193,209 | $39,620 |
| 2022 | 239 | 486 | 75 | 1.44 | $174,068 | $36,077 |
| 2021 | 208 | 402 | 74 | 1.44 | $168,205 | $40,906 |
| 2020 | 129 | 308 | 73 | 1.67 | $135,026 | $22,913 |
| 2019 | 128 | 281 | 73 | 1.37 | $36,748 | $19,618 |
| 2018 | 31 | 44 | 69 | 1.48 | $5,946 | $3,329 |
| 2017 | 203 | 621 | 70 | 3.64 | $260,395 | $32,676 |
| 2016 | 522 | 1,872 | 70 | 3.12 | $841,775 | $102,394 |
| 2015 | 638 | 2,601 | 70 | 2.94 | $1,082,660 | $139,372 |
| 2014 | 439 | 1,635 | 70 | 2.72 | $725,170 | $87,160 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 137 | $22,712 | $109 |
| Return visit (30+ min) | 111 | $8,887 | $61 |
| New patient visit (60+ min) | 45 | $6,176 | $137 |
2022: 6 services
| Return visit (30+ min) | 140 | $16,632 | $69 |
| New patient visit (60+ min) | 39 | $5,045 | $129 |
| Long return visit (40+ min) | 40 | $4,951 | $110 |
| Short return visit (20+ min) | 70 | $3,967 | $47 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,511 | $72 |
| New patient visit (45+ min) | 14 | $1,281 | $91 |
2021: 6 services
| Return visit (30+ min) | 129 | $19,533 | $87 |
| New patient visit (60+ min) | 46 | $7,608 | $165 |
| Long return visit (40+ min) | 44 | $6,288 | $137 |
| New patient visit (60+ min) | 12 | $2,046 | $170 |
| Short return visit (20+ min) | 25 | $1,658 | $57 |
| New patient visit (45+ min) | 13 | $1,497 | $115 |
2020: 4 services
| Return visit (30+ min) | 83 | $8,209 | $61 |
| Extended patient service without direct patient contact, first hour | 43 | $5,528 | $89 |
| Long return visit (40+ min) | 47 | $4,980 | $80 |
| New patient visit (60+ min) | 28 | $3,433 | $123 |
2019: 6 services
| New patient visit (60+ min) | 65 | $7,325 | $113 |
| Long return visit (40+ min) | 64 | $7,048 | $79 |
| Return visit (30+ min) | 60 | $4,845 | $58 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $121 | $10 |
| Test to determine lung volumes using sensors | 11 | $114 | $9 |
| Test to examine how well the lungs exchange gases | 11 | $84 | $7 |
2018: 2 services
| Long return visit (40+ min) | 12 | $1,007 | $84 |
| Return visit (30+ min) | 14 | $772 | $55 |
2017: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 140 | $22,023 | $49 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 68 | $6,250 | $89 |
| Short return visit (20+ min) | 44 | $1,600 | $35 |
| Test to measure expiratory airflow and volume | 15 | $251 | $17 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 432 | $71,732 | $48 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 215 | $22,232 | $91 |
| Short return visit (20+ min) | 49 | $2,747 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $2,285 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,437 | $120 |
| Test to measure expiratory airflow and volume | 23 | $584 | $25 |
2015: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 478 | $99,098 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 193 | $20,118 | $94 |
| Short return visit (20+ min) | 144 | $9,270 | $49 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,385 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $2,160 | $72 |
| Test to measure expiratory airflow and volume | 62 | $1,768 | $26 |
| New patient visit (30+ min) | 18 | $1,207 | $67 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 20 | $879 | $44 |
| Test to examine how well the lungs exchange gases | 20 | $788 | $39 |
| Test to determine lung volumes using sensors | 20 | $760 | $38 |
2014: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 369 | $68,595 | $49 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 117 | $11,899 | $94 |
| Short return visit (20+ min) | 45 | $2,431 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $1,485 | $67 |
| Test to measure expiratory airflow and volume | 20 | $513 | $26 |
Drugs they prescribed that Part D paid
$613,560
Pharmacies billed $613,560 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,101) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
315 generic and 786 brand-name prescriptions · $613,560 in drug cost · 42 antibiotic prescriptions to 25 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 212 | $200,702 | $947 |
| Anoro Ellipta | 72 | $58,854 | $817 |
| Breztri Aerosphere | 31 | $46,205 | $1,490 |
| Breo Ellipta | 66 | $35,478 | $538 |
| Spiriva Respimat | 30 | $25,482 | $849 |
See all 20 drugs
| Trelegy Ellipta | 212 | $200,702 | $947 |
| Anoro Ellipta | 72 | $58,854 | $817 |
| Breztri Aerosphere | 31 | $46,205 | $1,490 |
| Breo Ellipta | 66 | $35,478 | $538 |
| Spiriva Respimat | 30 | $25,482 | $849 |
| Combivent Respimat | 25 | $18,831 | $753 |
| Symbicort | 51 | $18,668 | $366 |
| Stiolto Respimat | 19 | $16,924 | $891 |
| Advair Hfa | 30 | $16,378 | $546 |
| Dulera | 15 | $7,093 | $473 |
| Albuterol Sulfate Hfa | 171 | $6,416 | $38 |
| Incruse Ellipta | 19 | $6,371 | $335 |
| Bevespi Aerosphere | 15 | $6,310 | $421 |
| Fluticasone-Salmeterol | 24 | $6,186 | $258 |
| Wixela Inhub | 31 | $3,484 | $112 |
| Ventolin Hfa | 33 | $2,395 | $73 |
| Montelukast | 87 | $1,042 | $12 |
| Azithromycin | 35 | $608 | $17 |
| Fluticasone Propionate | 19 | $225 | $12 |
| Prednisone | 32 | $67 | $2 |
Year by year
| 2024 | 1,101 | 206 | 0% (0) | 71% | $613,560 |
| 2023 | 1,033 | 208 | 0% (0) | 77% | $741,709 |
| 2022 | 967 | 209 | 0% (0) | 71% | $775,408 |
| 2021 | 811 | 174 | 0% (0) | 64% | $343,049 |
| 2020 | 712 | 131 | 0% (0) | 64% | $277,053 |
| 2019 | 783 | 166 | 0% (0) | 54% | $290,849 |
| 2018 | 599 | 126 | 0% (0) | 24% | $243,420 |
| 2017 | 145 | 37 | 0% (0) | 32% | $48,736 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Ofev | 15 | $213,765 | $14,251 |
| Trelegy Ellipta | 188 | $201,143 | $1,070 |
| Anoro Ellipta | 95 | $73,054 | $769 |
| Breo Ellipta | 80 | $53,454 | $668 |
| Combivent Respimat | 41 | $27,736 | $676 |
| Symbicort | 60 | $27,345 | $456 |
| Stiolto Respimat | 24 | $26,001 | $1,083 |
| Breztri Aerosphere | 24 | $23,039 | $960 |
| Advair Diskus | 22 | $19,224 | $874 |
| Spiriva Respimat | 17 | $15,311 | $901 |
| Incruse Ellipta | 34 | $13,089 | $385 |
| Wixela Inhub | 24 | $6,639 | $277 |
| Albuterol Sulfate Hfa | 161 | $6,388 | $40 |
| Fluticasone-Salmeterol | 15 | $5,938 | $396 |
| Ventolin Hfa | 40 | $2,840 | $71 |
| Montelukast | 64 | $1,609 | $25 |
| Azelastine | 15 | $475 | $32 |
| Fluticasone Propionate | 15 | $320 | $21 |
| Azithromycin | 13 | $108 | $8 |
| Prednisone | 20 | $100 | $5 |
2022: 20 drugs
| Ofev | 24 | $325,093 | $13,546 |
| Trelegy Ellipta | 148 | $156,365 | $1,057 |
| Anoro Ellipta | 61 | $50,985 | $836 |
| Breo Ellipta | 67 | $45,371 | $677 |
| Spiriva Respimat | 39 | $30,542 | $783 |
| Combivent Respimat | 46 | $26,386 | $574 |
| Incruse Ellipta | 41 | $23,119 | $564 |
| Symbicort | 34 | $18,712 | $550 |
| Advair Hfa | 21 | $14,424 | $687 |
| Spiriva Handihaler | 11 | $11,058 | $1,005 |
| Advair Diskus | 14 | $9,744 | $696 |
| Albuterol Sulfate Hfa | 150 | $7,983 | $53 |
| Wixela Inhub | 16 | $7,557 | $472 |
| Flovent Hfa | 11 | $5,433 | $494 |
| Ventolin Hfa | 44 | $2,954 | $67 |
| Montelukast | 57 | $1,424 | $25 |
| Fluticasone Propionate | 33 | $638 | $19 |
| Prednisone | 30 | $179 | $6 |
| Omeprazole | 11 | $124 | $11 |
| Azithromycin | 15 | $63 | $4 |
2021: 16 drugs
| Trelegy Ellipta | 84 | $80,965 | $964 |
| Breo Ellipta | 73 | $48,394 | $663 |
| Spiriva Respimat | 40 | $46,493 | $1,162 |
| Symbicort | 61 | $40,930 | $671 |
| Incruse Ellipta | 50 | $32,271 | $645 |
| Anoro Ellipta | 23 | $18,212 | $792 |
| Advair Hfa | 14 | $15,476 | $1,105 |
| Combivent Respimat | 17 | $11,747 | $691 |
| Flovent Hfa | 21 | $7,699 | $367 |
| Albuterol Sulfate Hfa | 124 | $6,192 | $50 |
| Azelastine | 26 | $2,536 | $98 |
| Ventolin Hfa | 25 | $1,835 | $73 |
| Montelukast | 86 | $1,776 | $21 |
| Fluticasone Propionate | 53 | $1,151 | $22 |
| Prednisone | 19 | $106 | $6 |
| Azithromycin | 11 | $80 | $7 |
2020: 15 drugs
| Breo Ellipta | 78 | $47,700 | $612 |
| Symbicort | 72 | $46,916 | $652 |
| Spiriva Respimat | 42 | $44,977 | $1,071 |
| Incruse Ellipta | 59 | $31,324 | $531 |
| Anoro Ellipta | 12 | $10,829 | $902 |
| Combivent Respimat | 15 | $7,585 | $506 |
| Advair Hfa | 14 | $6,676 | $477 |
| Wixela Inhub | 13 | $6,329 | $487 |
| Albuterol Sulfate Hfa | 72 | $4,028 | $56 |
| Ventolin Hfa | 39 | $2,603 | $67 |
| Fluticasone Propionate | 68 | $1,809 | $27 |
| Azelastine | 19 | $1,314 | $69 |
| Montelukast | 69 | $906 | $13 |
| Prednisone | 26 | $124 | $5 |
| Nystatin | 13 | $121 | $9 |
2019: 19 drugs
| Symbicort | 79 | $44,434 | $562 |
| Spiriva Respimat | 53 | $30,966 | $584 |
| Breo Ellipta | 44 | $23,401 | $532 |
| Incruse Ellipta | 38 | $16,821 | $443 |
| Spiriva | 16 | $11,503 | $719 |
| Stiolto Respimat | 19 | $7,906 | $416 |
| Flovent Hfa | 15 | $5,533 | $369 |
| Advair Diskus | 11 | $3,890 | $354 |
| Wixela Inhub | 12 | $2,786 | $232 |
| Mycophenolate Mofetil | 19 | $2,500 | $132 |
| Ventolin Hfa | 30 | $1,852 | $62 |
| Proair Hfa | 17 | $1,464 | $86 |
| Montelukast | 124 | $1,343 | $11 |
| Albuterol Sulfate Hfa | 25 | $1,175 | $47 |
| Azelastine | 19 | $1,147 | $60 |
| Fluticasone Propionate | 57 | $1,097 | $19 |
| Azithromycin | 27 | $260 | $10 |
| Nystatin | 13 | $175 | $13 |
| Prednisone | 30 | $157 | $5 |
2018: 18 drugs
| Itraconazole | 47 | $13,281 | $283 |
| Atovaquone | 12 | $11,856 | $988 |
| Symbicort | 20 | $9,603 | $480 |
| Valganciclovir | 11 | $1,922 | $175 |
| Ventolin Hfa | 19 | $1,040 | $55 |
| Proair Hfa | 17 | $1,038 | $61 |
| Mycophenolate Mofetil | 18 | $1,022 | $57 |
| Azithromycin | 34 | $396 | $12 |
| Pravastatin | 34 | $278 | $8 |
| Montelukast | 20 | $258 | $13 |
| Prednisone | 31 | $251 | $8 |
| Pantoprazole | 12 | $228 | $19 |
| Acyclovir | 28 | $173 | $6 |
| Sulfamethoxazole-Trimethoprim | 41 | $152 | $4 |
| Fluticasone Propionate | 13 | $129 | $10 |
| Alendronate | 22 | $103 | $5 |
| Gabapentin | 17 | $85 | $5 |
| Citalopram Hbr | 13 | $29 | $2 |
2017: 1 drug
| Acyclovir | 16 | $124 | $8 |
Money from drug and device companies
$509 in 2025
| 2025 | 2 | 5 | None | $509 |
| 2024 | 3 | 7 | None | $665 |
| 2022 | 2 | 3 | $435 | $477 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Breztri | $464 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $45 | 1 payment
|
See all 5 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-13 | Breztri | $113 |
| Regeneron Healthcare Solutions | Meals · 2025-05-19 | Dupixent | $45 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-09 | Breztri | $135 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-26 | None | $118 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-05 | Tezspire | $97 |
See earlier years (2024, 2022)
2024: $665
| Boehringer Ingelheim Pharmaceuticals | Ofev | $408 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $196 | 3 payments
|
| United Therapeutics | None | $61 | 1 payment
|
2022: $477
| Regeneron Healthcare Solutions | Dupixent | $451 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $26 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1710324694
- Licence
- CA 22896California A22896: Current · expires 2027-03-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-05-31
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5800 Hollis St, Emeryville, CA, 94608